Patent · US Active

Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis

US9017662B2 · kind B2 · utility

0Cited by

2References

2Claims

0Family size

Assignee

ACTOGENIX N.V. · BE

Inventors

Pieter Rottiers · Zevergem, BE
Klaas Vandenbroucke · Zevergem, BE

Key dates

Filing date	Aug 30, 2006
Grant date	Apr 28, 2015
Priority date	—
Expiry date	May 17, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/569
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as Lactobacillus sp. and Saccharomyces sp., are disclosed for the treatment of chronic enterocolitis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.